Understanding how ATF3 affects DNA repair and cancer prevention
ATF3 Regulation of Histone Acetylation in Genome Maintenance
This study is looking at how a protein called ATF3 helps with DNA repair in cancer cells, which could lead to better treatments for patients undergoing radiation or chemotherapy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Augusta University NIH-funded |
| Lab location | 1 site (Augusta, United States) |
| Project ID | NIH-11059995 on NIH RePORTER |
What this research studies
This research investigates the role of ATF3, a protein that responds to DNA damage, in regulating histone acetylation, which is crucial for DNA repair. By studying how ATF3 influences chromatin dynamics and the DNA damage response, the research aims to uncover new mechanisms that could enhance the effectiveness of cancer therapies like radiation and chemotherapy. The approach involves examining the interactions between ATF3, histone acetyltransferases, and the tumor suppressor protein p53 to better understand their collective impact on genome maintenance and tumor suppression.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients undergoing radiation or chemotherapy who may benefit from enhanced DNA repair mechanisms.
Not a fit: Patients with non-cancerous conditions or those not receiving DNA-damaging therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved cancer treatments by enhancing the body's ability to repair DNA damage caused by therapies.
How similar studies have performed: Previous research has shown that targeting DNA damage response mechanisms can significantly improve cancer treatment outcomes, indicating a promising avenue for this approach.
Where this research is happening
Augusta, United States
- Augusta University — Augusta, United States (Active)
Researchers
- Principal investigator: Yan, Chunhong — Augusta University
- Study coordinator: Yan, Chunhong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.